1,720,977 research outputs found
Systemic therapy for endometrial cancer
No full textFor fertility-sparing, conservative therapy of low-grade endometrioid endometrial cancer of clinical stage IA, high-dose progestins, given for at least 3-6 months, are the treatment of choice. For adjuvant therapy of surgically treated patients with endometrial cancer that has a high risk of recurrence, endocrine therapies have so far shown no efficacy. Similarly, the available evidence for the efficacy of adjuvant chemotherapies is rather weak. In only one study with well-operated patients with stage III or IV endometrial cancer could it be shown that adjuvant chemotherapy had greater efficacy than percutaneous radiotherapy. For stages I and 11, the efficacy of adjuvant chemotherapy (+/- brachytherapy +/- percutaneous radiotherapy) remains to be evaluated. For relapsed or disseminated endometrial cancer that can no longer be controlled by surgical or radiotherapeutic measures, systemic therapy is indicated. For well-differentiated tumors that express estrogen and/or progesterone receptors and that are not immediately life-threatening, high-dose progestins ( tamoxifen) are the treatment of first choice. Only when tumors are resistant to endocrine treatment or are acutely life-threatening should chemotherapy be used. Because multiple drug regimens achieve, at best, only a marginal increase in overall survival but definitely have a marked increase in toxicity, monochemotherapies are preferred in such cases
The operative treatment of massive atonic postoperative hemorrhage through Uterine compression stiches
No full textThe operative treatment of massive atonic postoperative hemorrhage through Uterine compression stiches
No full textModern therapy concepts for endometrial cancer
No full textMost cases of endometrial cancer (EC) become symptomatic at an early stage and have a good prognosis. EC has been traditionally treated with total abdominal hysterectomy plus bilateral salpingo-oophorectomy. For early stage, low grade cases (endometrioid, pT1a, pT1b; G1, G2) this is adequate therapy. For higher stages and grades, especially for type II EC (serous, clear cell) this therapy is insufficient. The efficacy of systematic pelvic and paraaortic lymphadenectomy for high risk EC, however, remains to be evaluated. External pelvic radiotherapy has been shown to improve local control in stage I and II EC, but has no positive effect on survival. A comparable improvement of local control can be achieved by vaginal brachytherapy with significantly less toxicity. Adjuvant chemotherapy is probably efficacious in EC. Its usefulness as exclusive adjuvant therapy or in combination with brachytherapy and/or external beam therapy remains to be evaluated by prospective trials
Inhibition of angiogenesis and breast cancer progression in vivo by an N-terminal 80 kDa recombinant fragment of human thrombospondin-2
No full textInhibition of breast cancer progression thought Throbospondin-2 over CD36 dependent induction of apoptotic of endothelial cell
No full textInhibition of breast cancer progression thought Throbospondin-2 over CD36 dependent induction of apoptotic of endothelial cell
No full textThrombospondin-2 inhibits Angiogenesis via a CD 36 receptor-dependent induction of Endothelial apoptoze
No full textThe impact of the time interval between two successive deliveries in an obstetric unit in terms of the mode of each delivery and the rate of perinatal mortality
No full textObjective: To analyze the relationship of the time interval between two deliveries, done by one obstetric team, on the delivery mode of the subsequent birth; to define the length of this interval; and to evaluate this time interval as a risk factor for increased perinatal mortality in a population-based cohort. Methods: All singleton deliveries at >= 24 weeks' gestation in Lower Saxony, Germany, between 2001 and 2005 (a total of 317,663 deliveries including 402 cases of perinatal mortality) were analyzed. The mode of the previous and the subsequent delivery, the time interval between the two deliveries, the time of birth, the hospital volume, and the existence of an affiliated neonatal ward were investigated. Results: When the first vaginal delivery was <45 min, there was a reduced probability that the subsequent birth would be a cesarean section. In case of a previous cesarean section, the cesarean rate of the following birth was influenced up to 165 min. In a multivariate analysis, vaginal deliveries following an earlier vaginal birth and occurring within <45 min were associated with increased perinatal mortality. Repeated cesarean sections within <165 min were associated with increased perinatal mortality when occurring at night or on weekends. Conclusion: A short time interval between two deliveries in an obstetric unit constitutes an independent risk factor for perinatal mortality
- …
